Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
Abstract Background Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in randomized clinical trials. Large-scale, real-world evidence in multi-...
Guardado en:
Autores principales: | Andreas Straube, Philipp Stude, Charly Gaul, Katrin Schuh, Mirja Koch |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4f7b5707f3f94856a2b455887d75c33c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
por: Andria Tziakouri, et al.
Publicado: (2021) -
Exploring the Hereditary Nature of Migraine
por: Bron C, et al.
Publicado: (2021) -
Letter to the Editor: The Case for Publicly Funded Headache Surgery in Germany
por: Leonard Knoedler, et al.
Publicado: (2021) -
The role of diet in the prevention of migraine attacks
por: O. O. Kopchak, et al.
Publicado: (2021) -
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
por: Timothy R. Smith, et al.
Publicado: (2021)